Shots:
- AbbVie has reported topline P-III (EPCORE DLBCL-1) trial results assessing epcoritamab vs chemoimmunotherapy (R-GemOx or BR) in 483 adults with r/r DLBCL, who had received ≥1L of therapy (73% had received ≥2L) & were ineligible for HDT-ASCT
- Trial showed improved PFS, with improvements across CRR, DoR, & time to next treatment, plus the study did not to demonstrate significant OS improvement. Also, AbbVie & Genmab to engage regulators & discuss next steps
- Epcoritamab (SC) is an IgG1 bispecific antibody built on Genmab’s DuoBody tech that simultaneously binds CD3 on T cells & CD20 on B cells to selectively redirect cytotoxic T cells & induce targeted killing of CD20-positive cells
Ref: AbbVie | Image: AbbVie | Press Release
Related News: AbbVie Enters PD-1×VEGF Bispecific Race with ~$5.6B Deal for Remegen’s RC148
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
